Topical Steroid Withdrawal: What It Is, Why It Is So Often Dismissed, and how to navigate it with Nutritional Therapy Support

If you are going through topical steroid withdrawal and feel like the medical system has left you without answers, you are not alone, and you are not imagining what is happening to your skin.

For a more accessible introduction to this topic, visit my Substack — Escape the Eczema Trap.

In this article, you’ll learn: – How topical steroid withdrawal (TSW) differs from an eczema flare, and why it is so often misdiagnosed. – What may be happening physiologically during withdrawal (including HPA axis suppression, neurogenic inflammation, and barrier disruption). – How nutritional therapy can support recovery by reducing inflammatory load and strengthening key repair pathways. This article is educational and is not a substitute for medical advice; seek urgent care if you develop signs of infection (rapidly spreading redness, fever, severe pain) or systemic deterioration.

Topical corticosteroids are the first-line treatment for eczema, and for many people they provide effective short-term symptom relief. But for a significant subset of patients, particularly those who have used moderate-to-high potency steroids over months or years, the process of stopping can trigger a severe and prolonged skin reaction that is distinct from their original eczema. This is topical steroid withdrawal (TSW).

TSW is also referred to as topical steroid addiction (TSA) or red skin syndrome (RSS). It remains inconsistently recognised across mainstream dermatology, in part because there is no single definitive test and clinical criteria are still evolving. As a result, many people experiencing a withdrawal-pattern reaction are told to continue or increase steroid use, which may temporarily suppress symptoms while prolonging the overall cycle.

The result is an often-isolating experience of serious symptoms without clinical validation or support.

What is topical steroid withdrawal?

TSW develops when the skin has adapted to regular topical corticosteroid exposure and then struggles to function without it. Prolonged steroid application suppresses the hypothalamic-pituitary-adrenal (HPA) axis, reduces the skin’s own anti-inflammatory capacity, and creates a state of physiological dependency. When steroids are stopped, the skin rebounds — often well beyond the original eczema area.¹²

Research by Xiao et al. characterised the acute withdrawal response as a “rebounding triad” of severe itching, dryness, and burning following sudden discontinuation. Critically, both the duration and frequency of prior corticosteroid use independently predicted severity: patients experiencing the rebounding triad had used topical steroids for a mean of 93.1 weeks, compared to 9.6 weeks in those who did not, with duration (OR = 1.83) and frequency of application (OR = 2.802) emerging as independent predictors in multivariate analysis.²

Systemic symptoms — fatigue, insomnia, thermoregulatory disturbances, mood disruption — are common and reflect broader HPA axis dysregulation. A prospective cohort study by Sheary and Harris following patients over two years found that stopping topical steroids had a large impact on quality of life for many months. The majority improved substantially by the two-year mark, though individual trajectories varied considerably, reflecting the complexity of the recovery process.⁴

How Topical Steroid Withdrawal differs from an eczema flare

One of the central challenges of TSW is that it can look superficially similar to an eczema flare, which is precisely why it is so often misdiagnosed. However, the clinical pattern is distinct in several important ways:

• Distribution: TSW typically spreads beyond the original eczema-affected areas, often involving the face, neck, and flexural areas even if the person’s eczema was historically more localised.
• Sensation: The predominant sensation in TSW is burning rather than itch, a neurogenic inflammatory process rather than the histamine-driven itch of classic eczema.
• Pattern: The “red sleeve” or “red face” distribution, diffuse erythema spreading from areas of heaviest steroid use, is characteristic of TSW and not typical of eczema.
• Trigger: Symptoms emerge or intensify specifically in relation to stopping or reducing steroids, not in response to the usual eczema triggers.
• Systemic presentation: Fatigue, chills, thermoregulation difficulty, and emotional dysregulation suggest a systemic process beyond localised skin inflammation.

The diagnostic gap: There is no specific diagnostic test for TSW. This means that in the absence of a positive test result, many clinicians default to the assumption that what they are seeing is an eczema flare, and prescribe more steroids. For patients already suffering the consequences of long-term steroid use, this represents a significant failure of clinical pattern recognition.

What is happening physiologically

Understanding the physiology of TSW helps to explain both why symptoms are so severe and why a systems-level approach to support, rather than symptom suppression, is clinically appropriate.

HPA axis suppression

Long-term use of topical corticosteroids, particularly high-potency preparations applied to large surface areas, suppresses endogenous cortisol production via HPA axis feedback. Clinical evidence for this is clear: in a cohort of 57 patients with severe atopic dermatitis managed with potent topical steroids, all patients treated with clobetasol propionate had suppressed cortisol levels at discharge. Following a structured tapering protocol, cortisol levels normalised at a mean of 41 days post-discharge, illustrating how long HPA axis re-regulation can take even under supervised conditions.³

Neurogenic inflammation and mitochondrial involvement

The characteristic burning pain of TSW, disproportionate to visible skin changes, points to neurogenic inflammatory pathways. Topical steroids suppress neuropeptide expression; when withdrawn, this suppression lifts and neurogenic pathways may become hyperactivated.

Emerging research published in the Journal of Investigative Dermatology (2025) suggests an additional mechanism: topical steroid withdrawal may be associated with an excess of mitochondrial NAD. This is an early but noteworthy finding that helps to explain why symptoms can be so systemic, and it may inform future clinical approaches as the evidence base develops.⁵

Skin barrier collapse

Prolonged topical steroid use thins the epidermis, reduces ceramide production, and impairs the skin’s structural proteins including filaggrin. During withdrawal, the barrier is left in a compromised state, highly permeable, prone to transepidermal water loss, and unable to mount an effective response to environmental triggers. Barrier repair is one of the lengthiest aspects of TSW recovery.³

Gut health and systemic inflammation

Long-term corticosteroid use, including topical application at scale, affects gut mucosal integrity and the composition of the gut microbiome. Dysbiosis and increased intestinal permeability compound the systemic inflammatory burden during withdrawal.

Many TSW patients report significant digestive symptoms alongside their skin presentation, and addressing gut health is a clinically meaningful lever during the recovery process.

Nutrient depletion

Corticosteroid use is associated with depletion of several key micronutrients, including zinc, vitamin D, vitamin C, and magnesium,, all of which play important roles in immune regulation, skin barrier function, and the inflammatory response. Restoring adequate nutrient status during TSW supports the body’s capacity for repair.

A clinical note on histamine and mast cells: Mast cell activation is frequently heightened during TSW. The withdrawal of steroids, which have a mast cell-stabilising effect, can trigger a surge in histamine release and broader mast cell reactivity. For patients with an underlying tendency towards histamine intolerance or mast cell activation syndrome (MCAS), this can significantly amplify TSW symptoms. Identifying and managing histamine load during withdrawal is an important part of clinical support.

Why TSW is so frequently dismissed

Despite a growing body of evidence and widespread patient experience, TSW is not currently recognised as a formal diagnosis in most mainstream dermatology guidelines. The reasons are partly systemic, topical steroids are among the most-prescribed dermatological treatments and their potential for dependency is not comfortably accommodated within a prescribing framework that relies on them.

The research that does exist confirms the clinical reality of withdrawal reactions. Xiao et al. documented a specific, reproducible pattern, the rebounding triad of itching, dryness, and burning, with clear dose-response relationships to duration and frequency of prior steroid use. Yet despite this evidence, TSW is not recognised as a formal diagnosis in most mainstream dermatological guidelines, and many patients continue to be told their symptoms represent an eczema flare rather than a withdrawal process.²

For patients, the practical consequence is that they present to their GP or dermatologist with clear, reproducible symptoms that began specifically when they stopped or reduced their steroids, and are told the evidence does not support their experience. Many are advised to resume steroid use, which temporarily suppresses symptoms but extends the dependency cycle.

In a significant step towards formal recognition, the United States announced dedicated ICD-10 diagnostic codes for topical steroid withdrawal syndrome in 2026 — codes L30.6 and T49.0X5S — due to come into effect in 2027. Whilst the UK has not yet followed suit, this represents a meaningful shift in how the condition is officially categorised, and reflects the growing body of clinical and patient evidence that can no longer be reasonably dismissed.

This is a familiar pattern in complex skin conditions. As with non-IgE-mediated hypersensitivity, the absence of a diagnostic test does not mean the absence of a clinical process. 

A clear, consistent, and reproducible pattern following a specific intervention, in this case, steroid cessation, is itself clinically meaningful.

How nutritional therapy can support you during TSW

Nutritional therapy cannot cure TSW or shorten its timeline. TSW resolves when the skin and HPA axis have fully re-established their own regulatory capacity, a biological process that unfolds in its own time. What nutritional support can do is reduce the inflammatory burden your body is carrying, address the nutrient deficiencies that compromise recovery, and support the multiple body systems that have been affected by long-term steroid use.

After twelve years of working with eczema and atopic conditions, I have identified ten systems that underlie most complex skin presentations. During TSW, several of these are typically involved simultaneously, which is why a personalised, investigative approach is more appropriate than a generic protocol.

What I look at clinically during Topical Steroid Withdrawal

• Gut health: Addressing dysbiosis, intestinal permeability, and the gut-skin signalling that drives systemic inflammation during withdrawal.
• Nutrient replenishment: Assessing and restoring key micronutrients depleted by long-term steroid use, particularly zinc, vitamin D, vitamin C, and magnesium, to support immune regulation and skin repair.
• Histamine and mast cell activity: Managing histamine load during a period when mast cell activation is often heightened; identifying dietary and environmental triggers that amplify reactivity.
• HPA axis and adrenal support: Supporting cortisol re-regulation through nutritional and lifestyle measures during the period of HPA axis recovery.
• Inflammation: Reducing systemic inflammatory burden through dietary and targeted supplementation, to make the withdrawal process more manageable.
• Barrier function: Supporting the skin’s structural repair through ceramide precursors, essential fatty acids, and nutrients that support epidermal integrity.
• Nervous system: Addressing the stress-cortisol-itch axis and supporting the nervous system during a process that carries a significant psychological burden alongside its physical symptoms.

Every TSW presentation is individual. The timeline, the severity, and the combination of systems most affected will vary considerably between clients. Clinical investigation, including functional testing where appropriate, allows me to understand what is most relevant for each person rather than applying a one-size-fits-all approach.

On the question of testing: Depending on what the clinical picture suggests, I may recommend stool analysis to assess gut microbiome health and permeability markers, nutrient status testing, or cortisol profiling (via DUTCH or salivary testing) to understand the degree of HPA axis suppression. Testing is not always necessary, sometimes the clinical history is sufficient, but it can significantly sharpen the protocol where the picture is complex.

An important note on topical steroid cessation

I do not advise stopping topical steroids without medical guidance. The decision to withdraw from steroids, and the way you do so, should be made in consultation with your GP or dermatologist. The approach to cessation (gradual taper, wet wrap supported, or cold turkey) has clinical implications, and I am not the right person to manage that decision.

What I offer is nutritional support during the agreed withdrawal process.

Working with me during TSW

Step 1 — Discovery & fit: we start with a discovery call to clarify what you are experiencing, what support you want, and whether I am the right practitioner for you. You can book here

Step 2 — Assessment: I take a detailed clinical history (including your steroid-use timeline, symptom pattern, diet, digestion, sleep, stress load, and any testing you have already completed) so we know what needs prioritising.

Step 3 — Protocol & reviews: you receive a personalised plan to reduce inflammatory load and support the systems most relevant to your presentation, with structured review sessions to adjust as your symptoms shift (because TSW is rarely linear).

Best fit: clients who want a personalised, investigative nutrition approach alongside medical care. Not the right fit: anyone looking for an emergency intervention, a guaranteed timeline, or advice on how to stop or taper topical steroids.

Considering nutritional support during TSW? The discovery call is an informal conversation about your history and what a clinical investigation might look like. It is the right starting point if you are unsure whether nutritional therapy is relevant to your situation, or if you would like to understand what working together would involve before making any decisions.

References

1.  Krafchik BR. Commentary [gradual tapering protocol in atopic dermatitis]. Pediatric Dermatology. 1996. https://doi.org/10.1111/j.1525-1470.1996.tb00738.x

2.  Xiao X, Xie H, Jian D, et al. Rebounding triad (severe itching, dryness and burning) after facial corticosteroid discontinuation defines a specific class of corticosteroid-dependent dermatitis. Journal of Dermatology. 2015. https://doi.org/10.1111/1346-8138.12877

3.  van Velsen SV, Haeck I, Bruijnzeel-Koomen C. Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitis. Journal of the American Academy of Dermatology. 2010. https://doi.org/10.1016/j.jaad.2009.12.048

4.  Sheary B, Harris MF. Cessation of long-term topical steroids in adult atopic dermatitis: a prospective cohort study. Dermatitis. 2020. https://doi.org/10.1097/DER.0000000000000602

5.  Shobnam N, Ratley G, Saksena S, et al. Topical steroid withdrawal is a targetable excess of mitochondrial NAD. Journal of Investigative Dermatology. 2025. https://doi.org/10.1016/j.jid.2024.11.026